Colorado biotechs reap bigger rounds; Amgen, Cytokinetics launch new study of cardiac muscle drug

@FierceBiotech: Combined vaccine has low seizure risk in babies. News | Follow @FierceBiotech

@JohnCFierce: Simos Simeonidis at Cowen says he's surprised by the VVUS vote, but "we see FDA approval by April 17 as pretty much a done deal." | Follow @JohnCFierce

@RyanMFierce: $VVUS bulls being handsomely rewarded this morning. Stock up 110.5% at last glance in a.m. trading. Story | Follow @RyanMFierce

@FierceMedDev: Colonoscopy Can Lower Rate of Cancer Deaths by Half. Story via @BloombergNews (see Enzo story). News | Follow @FierceMedDev

> New VC investments in Colorado-based biotech companies jumped in 2011, according to a local industry group. Six companies reaped $66.1 million versus a total of $45.6 million in 2010. Story

> Amgen ($AMGN) and Cytokinetics have launched an early-stage study of oral omecamtiv mecarbil, an experimental treatment intended to activate cardiac muscles. A IIb trial is under way for an IV formulation of the drug. Story

> University Hospitals Case Medical Center has signed on to help host a mid-stage study of Athersys' stem cell therapy for stroke. Report

Pharma News

@FiercePharma: Heinz might want pieces of the Pfizer nutrition business if they become available for antitrust reasons, FT reports. Story (reg. req.) | Follow @FiercePharma

> FDA adds 14 Chinese suppliers to heparin hot list. News

> $500M charge eats away at Ranbaxy's Q4 sales hike. Report

> CDC delay could temper adult uptake of Pfizer's Prevnar shot. Item

Vaccines News

> Vaccines mean that India celebrates its first year free of polio. Report

> World's first kala azar vaccine enters the clinic. Story

> Universal flu vaccine in first trial in the elderly, boosts responses. Item

> Nimenrix meningitis vaccine edges closer to the market for GSK. Article

> Prostate cancer vaccine teams up with antibody. Story

> Norovirus gets it in the nose. News

Manufacturing News

> Teva expected to pay big bucks for decision to use oversized vials. Report

> J&J Recall: Manufacturing issues believed behind CEO departure. Item

> Shire's $200 million Leed certified plant gets EMA nod. Story

> Pharmacists may seek arbitration to get recall costs from GSK. News

> Ranbaxy's manufacturing mess results in $606 million loss. Article

> FDA triples list of banned Chinese heparin ingredient makers. More

CRO News

> FDA cracks down on Chinese heparin material providers. News

> Ex-AstraZeneca researchers launch new CRO. Report

> ACRO blasts new rules that reveal docs' drug research payments. More

And Finally... New research shows that some Parkinson's patients can suddenly become much more creative when they take dopamine. But they can become so obsessed by their newfound passions that even simple daily chores go ignored. Release

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.